Citations to this article
Abstract
BACKGROUND. Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non–tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS. CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy. RESULTS. TFx associated with the number of bone metastases (median TFx = 0.014 with no bone metastases, 0.047 with 1–3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non–tumor-derived cfDNA track together and do not increase with generalized tissue damage from chemotherapy or radiation at the time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently maintained on secondary hormonal therapy was quite dynamic. CONCLUSION. TFx correlates with clinical features associated with overall survival in CRPC, and TFx decline is a promising biomarker for initial therapeutic response. TRIAL REGISTRATION. Dana-Farber/Harvard Cancer Center (DF/HCC) protocol no. 18-135. FUNDING. Wong Family Award in Translational Oncology, Dana Farber Cancer Institute Medical Oncology grant, Gerstner Family Foundation, Janssen Pharmaceuticals Inc., and Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (NCI).
Authors
Atish D. Choudhury, Lillian Werner, Edoardo Francini, Xiao X. Wei, Gavin Ha, Samuel S. Freeman, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Denisse Rotem, Christopher Lo, Mary-Ellen Taplin, Lauren C. Harshman, Zhenwei Zhang, Edward P. O’Connor, Daniel G. Stover, Heather A. Parsons, Gad Getz, Matthew Meyerson, J. Christopher Love, William C. Hahn, Viktor A. Adalsteinsson
Total citations by year
Citation information
Citations to this article (74)
| Title and authors | Publication | Year |
|---|---|---|
|
Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor
Takahashi N, Pongor L, Agrawal SP, Shtumpf M, Gurjar A, Rajapakse VN, Shafiei A, Schultz CW, Kim S, Roame D, Carter P, Vilimas R, Nichols S, Desai P, Figg Sr. WD, Bagheri M, Teif VB, Thomas A |
Genome Medicine | 2025 |
|
Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Fadlullah MZ, Nix D, Herberts C, Maurice-Dror C, Wyatt AW, Schmidt B, Fairbourn B, Tan AC, Wang L, Kohli M |
JNCI Cancer Spectrum | 2025 |
|
Liquid Biopsy as a Diagnostic and Monitoring Tool in Glioblastoma
Tataranu LG |
Medicina | 2025 |
|
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer
Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, Gianni C, Schepisi G, Brighi N, Lolli C, Cursano MC, Virga A, Casadei C, Altavilla A, Farolfi A, Ulivi P, Barone D, Matteucci F, De Giorgi U |
The Oncologist | 2025 |
|
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee ST, Scott AM, Martin AJ, Stockler MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW |
Nature medicine | 2025 |
|
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA
Virga A, Urbini M, Polano M, Petracci E, Tedaldi G, Gurioli G, Marisi G, Angeli D, Ambrosini-Spaltro A, De Luca G, Cangini I, Zampiga V, Cenacchi G, Toffoli G, Casadei C, Cursano MC, Conteduca V, De Giorgi U, Ulivi P |
Scientific Reports | 2025 |
|
Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management
Kopytov SA, Sagitova GR, Guschin DY, Egorova VS, Zvyagin AV, Rzhevskiy AS |
Cancers | 2025 |
|
Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
Yang H, Xiao X, Zeng L, Zeng H, Zheng Y, Wang J, Li G, Dai W, He Y, Wang S, Peng J, Chen W |
Journal of Translational Medicine | 2024 |
|
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW |
Nature Communications | 2024 |
|
Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers
Rickles-Young M, Tinoco G, Tsuji J, Pollock S, Haynam M, Lefebvre H, Glover K, Owen DH, Collier KA, Ha G, Adalsteinsson VA, Cibulskis C, Lennon NJ, Stover DG |
The Journal of molecular diagnostics : JMD | 2024 |
|
Genomic alterations and transcriptional phenotypes in circulating tumor DNA and matched metastatic tumor
Takahashi N, Pongor L, Agrawal SP, Shtumpf M, Rajapakse VN, Shafiei A, Schultz CW, Kim S, Roame D, Carter P, Vilimas R, Nichols S, Desai P, Figg WD Sr, Bagheri M, Teif VB, Thomas A |
2024 | |
|
Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.
Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N |
World journal of urology | 2024 |
|
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials.
Bayle A, Belcaid L, Cousin S, Trin K, Alame M, Rouleau E, Soubeyran I, Lacroix L, Blouin L, Vasseur D, Crombe A, Mathoulin-Pelissier S, Soria JC, Bellera C, Italiano A |
NPJ precision oncology | 2024 |
|
Liquid biopsy in cancer: current status, challenges and future prospects
Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, Sun T, Wei J |
Signal Transduction and Targeted Therapy | 2024 |
|
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Knutson TP, Luo B, Kobilka A, Lyman J, Guo S, Munro SA, Li Y, Heer R, Gaughan L, Morris MJ, Beltran H, Ryan CJ, Antonarakis ES, Armstrong AJ, Halabi S, Dehm SM |
Nature Communications | 2024 |
|
cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA.
Li S, Hu R, Small C, Kang TY, Liu CC, Zhou XJ, Li W |
Nature Protocols | 2023 |
|
Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, Priano I, Cedrés S, Martinez\u2010Marti A, Navarro A, Lenza L, Soleda M, Gonzalo\u2010Ruiz J, Vivancos A, Sansó M, Carcereny E, Morán T, Amat R, Felip E |
Molecular Oncology | 2023 |
|
Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction.
Ying M, Mao J, Sheng L, Wu H, Bai G, Zhong Z, Pan Z |
Journal of Personalized Medicine | 2023 |
|
Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer.
Du X, Fei X, Wang J, Dong Y, Fan L, Yang B, Chen W, Gong Y, Xia B, Zhu H, Wu F, Wang Y, Dong L, Zhu Y, Pan J, Yao X, Dong B |
Translational oncology | 2023 |
|
Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer.
Cani AK, Salami SS |
Cancer journal (Sudbury, Mass.) | 2023 |
|
Identifying the Common Cell-Free DNA Biomarkers across Seven Major Cancer Types.
Luo M, Liu Y, Zhao M |
Biology | 2023 |
|
Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated “Omics” Approaches to Explore Measurable Metrics
Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis AG, Soundararajan R, Tzelepi V |
Cancers | 2023 |
|
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES |
Clinical cancer research | 2023 |
|
Clinical translational research of liquid biopsy applications in prostate cancer and other urological cancers
Huang J, Huang D, Ruan X, Zhan Y, Chun ST, Ng AT, Na R |
2023 | |
|
The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization
Bronkhorst AJ, Holdenrieder S |
medizinische genetik | 2023 |
|
Aqueous Humor Liquid Biopsy as a Companion Diagnostic for Retinoblastoma: Implications for Diagnosis, Prognosis, and Therapeutic Options: Five Years of Progress
BERRY JL, PIKE S, SHAH R, REID MW, PENG CC, WANG Y, YELLAPANTULA V, BIEGEL J, KUHN P, HICKS J, XU L |
American Journal of Ophthalmology | 2023 |
|
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine
M Pagès, D Rotem, G Gydush, S Reed, J Rhoades, G Ha, C Lo, M Fleharty, M Duran, R Jones, S Becker, M Haller, CE Sinai, L Goumnerova, TR Golub, JC Love, KL Ligon, K Wright, VA Adalsteinsson, R Beroukhim, P Bandopadhayay |
Neuro-Oncology | 2022 |
|
Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples
E Stover, C Oh, P Keskula, A Choudhury, Y Tseng, V Adalsteinsson, J Lohr, A Thorner, M Ducar, G Kryukov, G Ha, M Rosenberg, S Freeman, Z Zhang, X Wu, E Allen, D Takeda, M Loda, C Wu, M Taplin, L Garraway, J Boehm, F Huang |
The Prostate | 2022 |
|
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer
V Tulpule, G Morrison, M Falcone, D Quinn, A Goldkorn |
Current Oncology Reports | 2022 |
|
The Significance of Neutrophil Extracellular Traps in Colorectal Cancer and Beyond: From Bench to Bedside
Li D, Shao J, Cao B, Zhao R, Li H, Gao W, Chen P, Jin L, Cao L, Ji S, Dong G |
Frontiers in Oncology | 2022 |
|
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Conteduca V, Casadei C, Scarpi E, Brighi N, Schepisi G, Lolli C, Gurioli G, Toma I, Poti G, Farolfi A, De Giorgi U |
Cancers | 2022 |
|
Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
Barbirou M, Miller AA, Gafni E, Mezlini A, Zidi A, Boley N, Tonellato PJ |
Scientific Reports | 2022 |
|
Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
Antonarakis ES, Tierno M, Fisher V, Tukachinsky H, Alexander S, Hamdani O, Hiemenz MC, Huang RS, Oxnard GR, Graf RP |
The Prostate | 2022 |
|
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Dopico PJ, Le MC, Burgess B, Yang Z, Zhao Y, Wang Y, George TJ, Fan ZH |
Biosensors | 2022 |
|
Preoperative Assessment and Perioperative Management of Resectable Gallbladder Cancer in the Era of Precision Medicine and Novel Technologies: State of the Art and Future Perspectives
Cassese G, Han HS, Yoon YS, Lee JS, Cho JY, Lee HW, Lee B, Troisi RI |
Diagnostics | 2022 |
|
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS, Li G, Tolba K, Bourla AB, Schulze K, Gadgil R, Fine A, Lofgren KT, Graf RP, Oxnard GR, Daniel D |
2022 | |
|
A patient-driven clinicogenomic partnership for metastatic prostate cancer
Crowdis J, Balch S, Sterlin L, Thomas BS, Camp SY, Dunphy M, Anastasio E, Shah S, Damon AL, Ramos R, Sosa DM, Small IK, Tomson BN, Nguyen CM, McGillicuddy M, Chastain PS, He MX, Cheung AT, Wankowicz S, Tewari AK, Kim D, AlDubayan SH, Dowdye A, Zola B, Nowak J, Manarite J, Gunn IH, Olson B, Lander ES, Painter CA, Wagle N, Van Allen EM |
2022 | |
|
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation
Kwan EM, Wyatt AW, Chi KN |
Frontiers in Oncology | 2022 |
|
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, Hiatt JB, Patton RD, De Sarkar N, Collier KA, Hoge AC, Chen K, Zimmer A, Weber ZT, Adil M, Reichel JB, Polak P, Adalsteinsson VA, Nelson PS, MacPherson D, Parsons HA, Stover DG, Ha G |
Nature Communications | 2022 |
|
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall'Olio FG, Madison RW, Fine AD, Oxnard GR, Graf RP, Stover DG |
2022 | |
|
Chromosome 6p amplification detected in blood cell-free DNA in advanced intraocular retinoblastoma
Sirivolu S, Xu L, Warren M, Prabakar RK, Shah R, Kuhn P, Hicks J, Berry JL |
Ophthalmic Genetics | 2022 |
|
Future directions for precision oncology in prostate cancer
Mizuno K, Beltran H |
The Prostate | 2022 |
|
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G |
Cancer Discovery | 2022 |
|
PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
Du XX, Dong YH, Zhu HJ, Fei XC, Gong YM, Xia BB, Wu F, Wang JY, Liu JZ, Fan LC, Wang YQ, Dong L, Zhu YJ, Pan JH, Dong BJ, Xue W |
Asian Journal of Andrology | 2022 |
|
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, Axcrona U, Axcrona K, Lothe RA, Skotheim RI |
International Journal of Cancer | 2022 |
|
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
R Makuku, N Khalili, S Razi, M Keshavarz-Fathi, N Rezaei, P Nistico |
Journal of Immunology Research | 2021 |
|
Diagnostic value of quantification of circulating free DNA for gall bladder cancer using a chemiluminescence DNA biosensor system based on DNA G-quadruplex/ hemin enzyme
H Ying, S Fengying, H Feng, W Yanhong, X Xianru, T Xiaolei |
Translational oncology | 2021 |
|
Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients
M Silvestri, C Reduzzi, G Feliciello, M Vismara, T Schamberger, C Köstler, R Motta, S Calza, C Ferraris, A Vingiani, G Pruneri, MG Daidone, CA Klein, B Polzer, V Cappelletti |
Cancers | 2021 |
|
An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma
L Sun, M Du, M Kohli, CC Huang, X Chen, M Xu, H Shen, S Wang, L Wang |
Frontiers in Oncology | 2021 |
|
LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
E Lakatos, H Hockings, M Mossner, W Huang, M Lockley, TA Graham |
iScience | 2021 |
|
Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy
EY Wong, L Xu, L Shen, ME Kim, A Polski, RK Prabakar, R Shah, R Jubran, JW Kim, JA Biegel, X Gai, P Kuhn, J Hicks, JL Berry |
npj Precision Oncology | 2021 |
|
Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer
Y Kubota, S Hatakeyama, T Yoneyama, MS Yoneyama, I Hamano, S Konishi, T Okamoto, H Yamamoto, T Yoneyama, Y Hashimoto, C Ohyama |
World Journal of Urology | 2021 |
|
Liquid Biopsy: It's the Bloody Truth!
NM Hawkey, AJ Armstrong |
Clinical cancer research | 2021 |
|
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
E Francini, FS Ou, J Rhoades, EG Wolfe, EP OConnor, G Ha, G Gydush, KM Kelleher, RS Bhatt, SP Balk, CJ Sweeney, VA Adalsteinsson, ME Taplin, AD Choudhury |
Cancers | 2021 |
|
Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
D Akahori, Y Inoue, N Inui, M Karayama, H Yasui, H Hozumi, Y Suzuki, K Furuhashi, T Fujisawa, N Enomoto, Y Nakamura, T Suda |
Scientific Reports | 2021 |
|
Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
S Li, ZS Noor, W Zeng, ML Stackpole, X Ni, Y Zhou, Z Yuan, WH Wong, VG Agopian, SM Dubinett, F Alber, W Li, EB Garon, XJ Zhou |
Nature Communications | 2021 |
|
Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study
A Abbas, M Gruner, J Karohl, PG Rose, A Joehlin-Price, D Stover, H Mahdi |
Frontiers in Oncology | 2021 |
|
Identification of Somatic Gene Signatures in Circulating Cell‐Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform
E Lin, AW Hahn, RH Nussenzveig, S Wesolowski, N Sayegh, BL Maughan, T McFarland, N Rathi, D Sirohi, G Sonpavde, U Swami, M Kohli, T Rich, O Sartor, M Yandell, N Agarwal |
The oncologist | 2021 |
|
The impact of DNA testing on management of patients with colorectal cancer
J Howe |
Annals of Gastroenterological Surgery | 2021 |
|
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer
I Casanova-Salas, A Athie, P Boutros, M Re, D Miyamoto, K Pienta, E Posadas, A Sowalsky, A Stenzl, A Wyatt, J Mateo |
European Urology | 2021 |
|
Genomic Profiling of Prostate Cancer: An Updated Review
Hatano K, Nonomura N |
The World Journal of Men's Health | 2021 |
|
Aqueous Humor as a Liquid Biopsy for Retinoblastoma: Clear Corneal Paracentesis and Genomic Analysis
Kim ME, Xu L, Prabakar RK, Shen L, Peng CC, Kuhn P, Gai X, Hicks J, Berry JL |
Journal of visualized experiments : JoVE | 2021 |
|
Genome‐wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis
T Wei, J Zhang, J Li, Q Chen, X Zhi, W Tao, J Ma, J Yang, Y Lou, T Ma, X Li, Q Zhang, W Chen, R Que, S Gao, X Bai, T Liang |
Molecular Oncology | 2020 |
|
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
N Sobhani, M Sirico, D Generali, F Zanconati, B Scaggiante |
World journal of clinical oncology | 2020 |
|
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
HA Parsons, J Rhoades, SC Reed, G Gydush, P Ram, P Exman, K Xiong, CC Lo, T Li, M Fleharty, GJ Kirkner, D Rotem, O Cohen, F Yu, M Fitarelli-Kiehl, KW Leong, ME Hughes, SM Rosenberg, LC Collins, KD Miller, B Blumenstiel, L Trippa, C Cibulskis, DS Neuberg, M DeFelice, SS Freeman, NJ Lennon, N Wagle, G Ha, DG Stover, AD Choudhury, G Getz, EP Winer, M Meyerson, NU Lin, I Krop, JC Love, GM Makrigiorgos, AH Partridge, EL Mayer, TR Golub, VA Adalsteinsson |
Clinical cancer research | 2020 |
|
Cell-Free DNA Tumor Fraction in the Aqueous Humor Is Associated With Therapeutic Response in Retinoblastoma Patients
A Polski, L Xu, RK Prabakar, JW Kim, R Shah, R Jubran, P Kuhn, D Cobrinik, J Hicks, JL Berry |
Translational Vision Science & Technology | 2020 |
|
Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA
F Mauger, C Horgues, M Pierre-Jean, N Oussada, L Mesrob, JF Deleuze |
Scientific Reports | 2020 |
|
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
S Dietz, P Christopoulos, Z Yuan, AK Angeles, L Gu, AL Volckmar, SJ Ogrodnik, F Janke, CD Fratte, T Zemojtel, MA Schneider, D Kazdal, V Endris, M Meister, T Muley, E Cecchin, M Reck, M Schlesner, M Thomas, A Stenzinger, H Sültmann |
EBioMedicine | 2020 |
|
Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study
RV Paemel, AD Koker, C Vandeputte, L van Zogchel, T Lammens, G Laureys, J Vandesompele, G Schleiermacher, M Chicard, NV Roy, A Vicha, GA Tytgat, N Callewaert, KD Preter, BD Wilde |
Epigenetics : official journal of the DNA Methylation Society | 2020 |
|
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
M Du, Y Tian, W Tan, L Wang, L Wang, D Kilari, CC Huang, L Wang, M Kohli |
Prostate Cancer and Prostatic Diseases | 2020 |
|
Simultaneous identification of clinically relevant RB1 mutations and copy number alterations in aqueous humor of retinoblastoma eyes
L Xu, L Shen, A Polski, RK Prabakar, R Shah, R Jubran, JW Kim, J Biegel, P Kuhn, D Cobrinik, J Hicks, X Gai, JL Berry |
Ophthalmic Genetics | 2020 |
|
Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
M Krumbholz, A Agaimy, R Stoehr, M Burger, S Wach, H Taubert, B Wullich, A Hartmann, M Metzler |
Disease Markers | 2019 |
|
Prospective Evaluation of the Concordance of Commercial Circulating Tumor DNA Alterations with Tumor-Based Sequencing across Multiple Soft Tissue Sarcoma Subtypes
B Demoret, J Gregg, DA Liebner, G Tinoco, S Lenobel, JL Chen |
Cancers | 2019 |
|
Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
SJ Bagley, SA Nabavizadeh, JJ Mays, JE Till, JB Ware, S Levy, W Sarchiapone, J Hussain, T Prior, S Guiry, T Christensen, SS Yee, ML Nasrallah, JJ Morrissette, ZA Binder, DM O'Rourke, AJ Cucchiara, S Brem, AS Desai, EL Carpenter |
Clinical cancer research | 2019 |
